HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $100 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.1%

Neg 0% Neu 88.1% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $100 price target.